A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever

Launched by CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY CO., LTD. · Nov 1, 2021

Keywords

ClinConnect Summary

This is a multicenter, open-label, single-arm, phase III study to evaluate the safety and efficacy of Amphotericin B liposomes in patients with persistent neutropenia and fever. About 93 patients will be recruited in this study. The patients will receive Amphotericin B liposomes intravenous infusion at a dose of 3 mg/kg over 2 hours once daily (qd) for a maximum of 12 weeks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18 \~ 75 years (inclusive), no gender limitation.
• • 2. Patients with neutrophilic deficiency after solid tumor chemotherapy, hematological tumor chemotherapy, hematopoietic stem cell transplantation, etc. (absolute neutrophil count (ANC) in peripheral blood \<500 /mm\^3 (0.5×10\^9 /L) for at least 72 hours at screening).
• • 3. Persistent or recurrent fever (oral temperature ≥38℃ or axillary temperature ≥37.7℃ within 24 hours prior to randomization) after at least 72 hours on broad-spectrum antibiotics, and considering fever to be associated with suspected fungal infection.
• 4. Female patients must meet one of the following conditions:
• • 1. Menopausal patients, menopause at least 1 year;
• • 2. Patients of childbearing age: Negative for blood/urine pregnancy test before enrollment; agree to take a guaranteed, effective contraception during the study and within 4 weeks after the study.
• • 5. Male patients and their partners must use effective contraception throughout the study period and up to 4 weeks after leaving the study.
• • 6. Patients fully understand and voluntarily participate in this study and sign informed consent.
• Exclusion Criteria:
• • 1. History of allergy to liposomes or amphotericin B.
• • 2. Received systemic treatment of amphotericin B or amphotericin B-containing formulation within 10 days prior to enrollment.
• • 3. Liposome used within 1 month before the signing informed consent.
• • 4. Confirmed or clinically diagnosed invasive fungal infection or known uncontrolled bacteremia or sepsis at screening.
• • 5. Eastern Cooperative Oncology Group (ECOG) performance status ≥3;
• • 6. Abnormal liver function, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≥5 × the upper limit of normal (ULN), or ALT/AST ≥3 × ULN with total bilirubin ≥1.5 × ULN, or total bilirubin ≥3 × ULN.
• • 7. Serum creatinine \> 2 × ULN.
• • 8. Serum potassium concentration ≤3.0 mmol/L prior to the first administration, or serum potassium concentration ≤the lower limit of normal value (LLN) in patients undergoing digitalization.
• • 9. 12-lead ECG presenting II or III degree atrioventricular block, long QT syndrome or corrected QT interval\>480 ms in the absence of a pacemaker.
• • 10. Cardiac function grade III/IV (NYHA).
• • 11. Tachyarrhythmia requiring intervention and a history of high-risk coronary heart disease such as unstable angina and acute coronary syndrome.
• • 12. Human immunodeficiency virus (HIV) antibody or treponema pallidum specific antibody (TPHA) positive; active tuberculosis on CT of chest (to be determined by investigator).
• • 13. Pregnant or lactating female.
• • 14. A history of drug abuse (non-medical use of narcotic drugs or psychotropic substances) or drug dependence (narcotics, stimulants and psychotropic substances, etc.) within 2 years.
• • 15. Plan to use prohibited drugs during the study period.
• • 16. Enrolled in any other clinical trials of drugs or medical devices within 3 months prior to screening.
• • 17. Life expectancy \< 2 months;
• • 18. Not suitable for this study as decided by the investigator due to other reasons